Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking approach to diabetes management. These innovative therapies function by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these substances boost insulin production and suppress

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing differences in their pharm